Decades of Playbook, Under Review

Much of what pharmaceutical manufacturers know about bringing a product to market was learned in a commercial environment that no longer exists. Pharmaceutical Commerce's October 2026 issue looks at which of those lessons are being rewritten.

Pricing has moved quickest. Most favored nation agreements now cover 26 manufacturers, following nine additional signatories on Aug. 31, 2026. Separately, the high-list, high-rebate structure that has governed brand strategy is proving less reliable than it once was, and not only for the reasons manufacturers expected. Payers, meanwhile, now negotiate against price points they can actually see, with direct-to-patient cash prices and Medicare's Maximum Fair Price among them.

A second set of questions concerns how manufacturers reach patients and prescribers, as well as how they know whether any of it is working. Access leaders report strong interest in AI-forward partners, but a clear majority describe what they actually want as smarter, adaptive execution rather than just the technology itself. Real-world evidence runs into a related problem. The industry generates plenty of it, and very little reaches a clinician at the moment a prescribing decision is being made.

Elsewhere, practice is simply outrunning the structures built to support it. Policy can swiftly change a vaccine schedule, while standing up new manufacturing capacity and licensing pathways takes years. Direct-to-patient programs are scaling faster than the compliance frameworks meant to govern them. On the distribution side, the change is more incremental but no less real, as AI-native platforms flag and route around shipment risk before it becomes an exception.

The articles in this issue follow three distinct storylines: a pricing model losing its old certainties, an engagement layer being asked to prove its returns, and a set of operations expanding faster than the frameworks around them.